X0306 4 2016-05-09 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001410289 Szela Mary T C/O AEGERION PHARMACEUTICALS, INC. ONE MAIN STREET, SUITE 800 CAMBRIDGE MA 02142 1 1 0 0 Chief Executive Officer Stock Option (right to buy) 2.46 2016-05-09 4 A 0 194000 0.00 A 2026-05-09 Common Stock 194000 194000 D Restricted Stock Units 2016-05-09 4 A 0 97000 0.00 A Common Stock 97000 97000 D The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant. 25% of the shares of common stock underlying this stock option award will vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 9, 2017, 33.33% of the units vesting on May 9, 2018, and 33.33% of the units vesting on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Jennifer Fitzpatrick, attorney-in-fact 2016-05-11